$2.40
0.42% yesterday
Nasdaq, Jul 15, 10:00 pm CET
ISIN
US23284F1057
Symbol
CTMX
Sector
Industry

CytomX Therapeutics, Inc. Stock price

$2.40
-0.06 2.44% 1M
+1.54 179.72% 6M
+1.37 133.01% YTD
+0.99 70.21% 1Y
+0.90 60.00% 3Y
-6.43 72.82% 5Y
-10.50 81.40% 10Y
-10.50 81.40% 20Y
Nasdaq, Closing price Tue, Jul 15 2025
+0.01 0.42%
ISIN
US23284F1057
Symbol
CTMX
Sector
Industry

Key metrics

Basic
Market capitalization
$376.5m
Enterprise Value
$296.6m
Net debt
positive
Cash
$79.9m
Shares outstanding
80.6m
Valuation (TTM | estimate)
P/E
5.0 | negative
P/S
2.6 | 4.2
EV/Sales
2.0 | 3.3
EV/FCF
negative
P/B
15.0
Financial Health
Equity Ratio
-0.4%
Return on Equity
-6,988.8%
ROCE
74.5%
ROIC
-240.1%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$147.6m | $90.0m
EBITDA
$37.7m | $19.4m
EBIT
$36.0m | $-4.8m
Net Income
$41.6m | $-17.5m
Free Cash Flow
$-81.5m
Growth (TTM | estimate)
Revenue
23.8% | -34.8%
EBITDA
192.8% | -27.6%
EBIT
232.3% | -119.0%
Net Income
151.7% | -154.8%
Free Cash Flow
11.7%
Margin (TTM | estimate)
Gross
-
EBITDA
25.5% | 21.5%
EBIT
24.4%
Net
28.2% | -19.4%
Free Cash Flow
-55.3%
More
EPS
$0.5
FCF per Share
$-1.0
Short interest
13.7%
Employees
120
Rev per Employee
$1.2m
Show more

Is CytomX Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

CytomX Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a CytomX Therapeutics, Inc. forecast:

10x Buy
83%
2x Hold
17%

Analyst Opinions

12 Analysts have issued a CytomX Therapeutics, Inc. forecast:

Buy
83%
Hold
17%

Financial data from CytomX Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
148 148
24% 24%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 31 31
5% 5%
21%
- Research and Development Expense 80 80
2% 2%
54%
38 38
193% 193%
26%
- Depreciation and Amortization 1.69 1.69
17% 17%
1%
EBIT (Operating Income) EBIT 36 36
232% 232%
24%
Net Profit 42 42
152% 152%
28%

In millions USD.

Don't miss a Thing! We will send you all news about CytomX Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CytomX Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
about 2 months ago
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 2:35 p.m. ET.
Neutral
GlobeNewsWire
about 2 months ago
SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the first patient has been dosed with CX-801 in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in the ongoing Phase 1 dose escalation study (NCT06462794) evaluating safety and init...
Positive
Seeking Alpha
2 months ago
CytomX Therapeutics' CX-2501 shows promising phase 1 results in refractory colorectal cancer, with a 27.8% objective response rate and manageable toxicity. CTMX's financial position strengthened by a $100 million stock offering, extending cash runway through 2025. CX-904 development with Amgen discontinued, but collaboration continues on a preclinical T-cell engager project.
More CytomX Therapeutics, Inc. News

Company Profile

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Head office United States
CEO Sean McCarthy
Employees 120
Founded 2010
Website cytomx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today